Yasui, K.; Takagi, K.; Fuji, T.; Nishiyama, T.; Nagai, Y.; Matsumoto, K.; Horiguchi, S.; Fujii, Y.; Otsuka, M.; Fujiwara, T.
Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Cancers 2025, 17, 3287.
https://doi.org/10.3390/cancers17203287
AMA Style
Yasui K, Takagi K, Fuji T, Nishiyama T, Nagai Y, Matsumoto K, Horiguchi S, Fujii Y, Otsuka M, Fujiwara T.
Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Cancers. 2025; 17(20):3287.
https://doi.org/10.3390/cancers17203287
Chicago/Turabian Style
Yasui, Kazuya, Kosei Takagi, Tomokazu Fuji, Takeyoshi Nishiyama, Yasuo Nagai, Kazuyuki Matsumoto, Shigeru Horiguchi, Yuki Fujii, Motoyuki Otsuka, and Toshiyoshi Fujiwara.
2025. "Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma" Cancers 17, no. 20: 3287.
https://doi.org/10.3390/cancers17203287
APA Style
Yasui, K., Takagi, K., Fuji, T., Nishiyama, T., Nagai, Y., Matsumoto, K., Horiguchi, S., Fujii, Y., Otsuka, M., & Fujiwara, T.
(2025). Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Cancers, 17(20), 3287.
https://doi.org/10.3390/cancers17203287
